Iain Ross was appointed to the Board as Non-Executive Chairman in July 2021. He assumed Executive responsibility in January 2023 following the departure of Chief Executive Officer.
Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons and Hoffman La Roche before moving into the biotechnology sector where he has been Chairman, CEO and Director of several international biotechnology companies including Kazia Therapeutics Limited, Celltech Group plc, Quadrant Healthcare plc and Redx Pharma plc.
Currently he is Non-Executive Chairman at Silence Therapeutics PLC (NASDAQ); and a non-executive director of BiVictriX Therapeutics plc (LSE). Mr Ross is a qualified Chartered Director, Fellow of the Institute of Directors and Honorary Fellow of Royal Holloway, London University.
John Hawkins was appointed Chief Financial Officer in September 2022. John joined ReNeuron in October 2014 as Financial Controller and was appointed Company Secretary in June 2021.
John is an experienced finance professional with a breadth of experience gained within a variety of businesses, from large PLCs to family-owned SMEs. He joined ReNeuron, after leaving his role as Finance Director of an insurance business, having previously worked for a number of years in the financial services sector where he specialised in business partnering, helping to drive growth and profitability. During this time, he played a lead role in a number of acquisitions and played a key role in the $1bn sale of a division of Standard Chartered Bank to The Lloyds Banking Group.
John graduated from university with a 1st class honours degree in industrial chemistry and started his career with KPMG, where he qualified as a Chartered Accountant.
Dr Randolph Corteling was appointed Chief Scientific Officer in September 2022, after re-joining ReNeuron as VP of Research in March 2022.
Randolph has 24 years’ experience in medical research and drug discovery, spanning academia, biotechnology and the pharmaceutical industry. He gained his PhD in Medical and Surgical Sciences at Nottingham University, followed by three years as a Heart and Stroke Foundation Postdoctoral Fellow at the University of Calgary, Canada.
In 2007 he joined ReNeuron as a senior member of the research team where he established a deep understanding of stem cell biology and in particular the role of extracellular vesicles in cell-to-cell communication. In 2011 he was appointed Head of Cell Biology where he established the first exosome programmes at ReNeuron, which are now a major commercial opportunity for the Company. He was later promoted to Head of Research at ReNeuron.
Randolph has re-joined ReNeuron from Evox Therapeutics, a private company focused on Exosome based therapeutics for rare diseases, where he led their Disease Biology and Exosome Payloads teams.
Simon Dew was appointed Chief Business Officer in November 2022.
Simon joined ReNeuron from Mereo BioPharma Plc, where he was Vice President Business and Corporate Development. Prior to that he was Vice President Business Development at Evox Therapeutics, where he was responsible for several transformative deals in the exosome space.
Simon has over 25 years’ experience in pharmaceutical Business Development, Corporate Development and Corporate Strategy, responsible for multiple BD&L and M&A transactions.
Over his career, he has held senior leadership roles in Pharma and Biotech, including VP Corporate Strategy at Gyroscope Therapeutics, prior to its acquisition by Novartis and as SVP Corporate Strategy and Business Development as Astellas Pharmaceuticals, as well as operational leadership roles in Quintiles (IQVIA), Parexel, Phytopharm plc and GSK/SB, in Europe and in international markets
He is currently on the Business Development Board of Sunstone Capital a Danish Venture Capital Company.
He holds a degree in Pharmacy and is a member of the Royal Pharmaceutical Society of Great Britain
Suzanne Hancock was appointed Chief Operations Officer in September 2022. Suzanne joined ReNeuron as a Programme Manager in 2017 and held the Head of Operations role from 2020.
Suzanne has broad experience of both leadership and technical scientific roles. She joined ReNeuron from GE Healthcare, where she spent almost twelve years and held a number of managerial roles forming and leading global cross functional teams engaged in the development and delivery of new products in the Life Sciences and Cell Therapy industry. Suzanne began her career as a scientist with Amersham International where she was involved in developing cell based assays and high content image analysis platforms for drug development.
She holds a BSc in Applied Biological Sciences and in 2019 successfully completed an MSP Practitioner qualification at Cardiff University.
Professor Stefano Pluchino was appointed Chair of the Scientific Advisory Board in September 2022, after having previously been in the role of Chief Scientific Officer from May 2021.
He is Reader in Regenerative Neuroimmunology and Honorary Consultant at the University of Cambridge since 2010. He obtained his MD and PhD at the University of Siena, Italy, and progressed to two consecutive post doctorate appointments at the San Raffaele Scientific Institute in Milan.
Stefano has published over 120 peer-reviewed papers and is internationally recognised as a leader and pioneer in the field of regenerative neuroimmunology. He was the recipient of the 2003 European Charcot Foundation (ECF) Award, the 2006 Sorono Foundation Multiple Sclerosis Award, the 2007 Rita Levi-Montalcini Award, the 2009 Italian Ministry of Health Young Investigator Award and the 2010 International Royan Award for outstanding research in Stem Cell Biology and Technology.